Patents by Inventor Mi Young Cha

Mi Young Cha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE
    Publication number: 20260191982
    Abstract: The present disclosure relates to an anti-basal cell adhesion molecule (BCAM) antibody-drug conjugate where the anti-BCAM antibody is conjugated to an antitumor compound via a linker, a pharmaceutical composition comprising the anti-BCAM antibody-drug conjugate, and a method for treating cancer by administering an effective amount of the anti-BCAM antibody-drug conjugate to a subject in need thereof.
    Type: Application
    Filed: November 17, 2023
    Publication date: July 9, 2026
    Applicants: Genome & Company, Inc., Debiopharm Research & Manufacturing SA
    Inventors: Mi Young Cha, Hyunkyung Yu, Hyunuk Kim, Youngeun Ha, Kitae Park, Bunam Jeon, Yun Yeon KIM, Léo Marx, Mathilde Pantin, Nathalie Bellocq, Frederic Levy
  • NOVEL TARGET FOR ANTI-CANCER AND IMMUNE-ENHANCING
    Publication number: 20260184774
    Abstract: The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351.
    Type: Application
    Filed: March 12, 2026
    Publication date: July 2, 2026
    Applicant: Genome and Company
    Inventors: Bu-Nam JEON, Yun Yeon Kim, Suro Lee, Youn Kyung Houh, Joo-Yeon Chung, Areum Jeong, Mi Young Cha
  • Target for anti-cancer and immune-enhancing
    Patent number: 12600765
    Abstract: The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: April 14, 2026
    Assignee: GENOME AND COMPANY
    Inventors: Bu-Nam Jeon, Yun Yeon Kim, Suro Lee, Youn Kyung Houh, Joo-Yeon Chung, Areum Jeong, Mi Young Cha
  • ANTI-CNTN4-SPECIFIC ANTIBODIES AND USE THEREOF
    Publication number: 20240209081
    Abstract: The present invention relates to anti-CNTN4 antibodies or antigen-binding fragments thereof, and use thereof for activating T cells that upregulate a cell-mediated immune response, for example, use thereof for the treatment of cancer.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 27, 2024
    Applicant: GENOME AND COMPANY
    Inventors: Bu Nam JEON, Youn Kyung HOUH, Yun Yeon KIM, Mi Young CHA
  • ANTI-BCAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20240209112
    Abstract: The present invention relates to an anti-BCAM antibody or an antigen-binding fragment thereof, and uses thereof. In addition, the anti-BCAM antibody or antigen-binding fragment thereof according to the present invention can be used for preventing or treating a state associated with cells expressing BCAM, for example, cancer.
    Type: Application
    Filed: June 1, 2021
    Publication date: June 27, 2024
    Applicant: GENOME AND COMPANY
    Inventors: Mi Young CHA, Hyunkyung YU, Bu Nam JEON, Hyunuk KIM
  • ANTI-CNTN4 ANTIBODY AND USE THEREOF
    Publication number: 20240182563
    Abstract: The present invention relates to an anti-CNTN4 antibody or an antigen-binding fragment thereof, a pharmaceutical composition containing the same, and a use thereof for activating T cells upregulating cell-mediated immune responses, for example, for treating cancer.
    Type: Application
    Filed: April 5, 2022
    Publication date: June 6, 2024
    Applicant: GENOME AND COMPANY
    Inventors: Bu Nam JEON, Joo Yeon CHUNG, Soo Jung MOON, Hyunuk KIM, Mi Young CHA, Junho CHUNG, Junyeong JIN, Soohyun KIM, Jisu CHAE
  • NOVEL TARGET FOR ANTI-CANCER AND IMMUNE-ENHANCING
    Publication number: 20210230256
    Abstract: The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351.
    Type: Application
    Filed: April 9, 2021
    Publication date: July 29, 2021
    Applicant: GENOME AND COMPANY
    Inventors: Bu-Nam JEON, Yun Yeon KIM, Suro LEE, Youn Kyung HOUH, Joo-Yeon CHUNG, Areum JEONG, Mi Young CHA
  • IRAK4 inhibitor and use thereof
    Patent number: 10988482
    Abstract: The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: April 27, 2021
    Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Baoyu Xue, Runa Zheng, Mi Young Cha, Maengsup Kim
  • IRAK4 INHIBITOR AND USE THEREOF
    Publication number: 20200062775
    Abstract: The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.
    Type: Application
    Filed: August 13, 2015
    Publication date: February 27, 2020
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Baoyu Xue, Runa Zheng, Mi Young Cha, Maengsup Kim
  • IRAK4 inhibitor and use thereof
    Patent number: 10562902
    Abstract: Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: February 18, 2020
    Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.
    Inventors: Jiangcheng Xu, Qinguan Cai, Mi Young Cha, Maengsup Kim
  • N-benzoate group substituted benzopyrroline-2-one derivative and use thereof
    Patent number: 10322108
    Abstract: Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR? mediated disease. The compound has the structural formula (I).
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 18, 2019
    Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.
    Inventors: Hai Xue, Tao Zhao, Mi Young Cha, Maengsup Kim
  • Compound inhibiting activities of BTK and/or JAK3 kinases
    Patent number: 10273242
    Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: April 30, 2019
    Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
  • IRAK4 INHIBITOR AND USE THEREOF
    Publication number: 20180244677
    Abstract: Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I.
    Type: Application
    Filed: August 12, 2016
    Publication date: August 30, 2018
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jiangcheng XU, Qinguan CAI, Mi Young CHA, Maengsup KIM
  • COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES
    Publication number: 20180051036
    Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
    Type: Application
    Filed: October 31, 2017
    Publication date: February 22, 2018
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jinming LIU, Mi Young CHA, Gong LI, Zhanmei LI, Hongjuan QIU, Maengsup KIM
  • N-BENZOATE GROUP SUBSTITUTED BENZOPYRROLINE-2-ONE DERIVATIVE AND USE THEREOF
    Publication number: 20170368028
    Abstract: Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR? mediated disease. The compound has the structural formula (I).
    Type: Application
    Filed: January 22, 2016
    Publication date: December 28, 2017
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Hai Xue, Tao Zhao, Mi Young Cha, Maengsup Kim
  • Compound inhibiting activities of BTK and/or JAK3 kinases
    Patent number: 9840517
    Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: December 12, 2017
    Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
  • BIFUNCTIONAL FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF
    Publication number: 20160340422
    Abstract: The present invention provides a bifunctional fusion protein comprising the extracellular region of CTLA4 and an anti-IL-17 antibody, a gene encoding the protein, a vector comprising the gene, a host cell comprising the vector, and a pharmaceutical composition containing the protein.
    Type: Application
    Filed: January 28, 2015
    Publication date: November 24, 2016
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Guoqiang Chen, Jiawang Liu, Nanmeng Song, Yaping Yang, Mi Young Cha
  • NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY
    Publication number: 20160229868
    Abstract: A novel fused pyrimidine derivative has an inhibitory activity for tyrosine kinases. A pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases contains the fused pyrimidine derivative as an active ingredient.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Applicant: HANMI SCIENCE CO., LTD
    Inventors: Mi Young CHA, Seok Jong KANG, Mi Ra KIM, Ju Yeon LEE, Ji Young JEON, Myoung Gi JO, Eun Joo KWAK, Kwang Ok LEE, Tae Hee HA, Kwee Hyun SUH, Maeng Sup KIM
  • COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES
    Publication number: 20160229865
    Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
    Type: Application
    Filed: September 18, 2014
    Publication date: August 11, 2016
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
  • Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
    Patent number: RE46511
    Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: August 15, 2017
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim